

Hepatoselüler Karsinoma

Cerrahi Tedavi: Rezeksiyon ve Transplantasyon

Dr. Turan Kanmaz

Memorial Şişli Hastanesi Karaciğer Nakli Merkezi, İstanbul

3. TÜRKİYE-AZERBAYCAN HEPATOLOJİ KURSU

29-20 Eylül 2017, İstanbul

Cerrahi Tedavi





Fig. 2. The BCLC staging system for HCC. M, metastasis classification; N, node classification; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

Rezeksiyona uygun adaylar


- Kompanse KC hastalığı
- Asemptomatik
- Tek lezyon
- Normal bilirubin
- Portal hipertansiyon bulgusu yok
- Eşlik eden sistemik hastalık yok
- Sınırlı/düşük riskli rezeksiyon
- Kısa ameliyat zamanı

ABD, Fransa ve Japonya rezeksiyon sonuçları

- Benzer sağkalım
 - 5y %31-41
- ABD'de daha büyük tm
 - 8cm vs. 6 ve 3.5cm
- ABD'de HCV'li az
 - %20 vs %38 ve %74
- Sirotik hastada
 - %23 vs %52 ve %65



Rezeksiyon sonrası KC nakli, 5 y sağkalım



Rezeksiyon vs KC Nakli

Author/year	Number LR	Number OLT	Recurrence LR	Recurrence OLT
Iwatsuki 1991	76	105	50%	42.9%
Michel 1995	20	21	70%	14.3%
Vargas 1995	35	11	40%	0%
Tan 1995	12	15	25%	20%
Otto 1998	52	50	53.8%	36.0%
Llovet 1999	77	87	33.8%	2.3%
Weimann 1999	32	31	18.8%	0%
Figueras 2000	35	85	65%	0%
DeCarlis 2001	154	121	47.4%	9%

Wong LL. *Amer J Surgery*. 2002;183:309-16

Rezeksiyon vs KC Nakli

Author/year	Number LR	Number OLT	3-year survival LR (%)	3-year survival OLT (%)	5-year survival LR (%)	5-year survival OLT (%)
Ringe 1991	131	61	42.3	15.2	35.8	15.2
Iwatsuki 1991	76	105	47.2	39.2	32.9	35.6
Bismuth 1993	60	61	49	49		
Michel 1995	20	21	77	72	41	72
Vargas 1995	35	11				
Tan 1995	12	15	33	63	34-51%	60-69%
Otto 1998	52	50	40	47		
Llovet 1999	77	87	62	69		
Weimann 1999	32	31	41.3	71.7		
Figueras 2000	35	85	57	74	51	60
DeCarlis 2001	154	121			46.1	63.6


Wong LL. *Amer. J Surgery*. 2002;183:309-16

Memorial Şişli Hastanesi HCC deneyimi

Eylül 2006 - Eylül 2017

- Toplam KC nakli : 1039 (1000 hastada)
- HCC'li hasta : 192
- Değerlendirilen : 174
 - Canlıdan : 115 (%66)
 - Kadavradan : 59 (%34)


Etyoloji




Genel sağkalım: 174 hasta (Kaplan-Meier)

- Genel sağkalım: 79,9%

- 1-y : 86,4%
- 3-y : 81,6%
- 5-y : 76,0%



Verici tipine göre sağkalım (canlı/kadavra)






Overall Comparisons

	Chi-Square	df	Sig.
Log Rank (Mantel-Cox)	1,914	1	,167

Test of equality of survival distributions for the different level kadcan.


AFP'ye göre sağkalım

Case Processing Summary




Tümör sayısına göre sağkalım

1 tm:	n=97
	1 y : 88,4%
	3 y : 87,2%
	5 y : 80,5%
2 tm:	n=33
	1 y : 74,6%
	3 y : 67,3%
	5 y : 67,3%
3 tm:	n=15
	1 y : 93,3%
	3 y : 78,8%
	5 y : 78,8%
≥4 tm:	n=29
	1 y : 86,1%
	3 y : 81,5%
	5 y : 70,8%



TMNO	Total N	N of Events	Censored	
			N	Percent
1	97	15	82	84,5%
2	33	10	23	69,7%
3	15	3	12	80,0%
≥4	29	7	22	75,9%
Overall	174	35	139	79,9%


MELD'e göre sağkalım



MELD	Total N	N of Events	Censored	
			N	Percent
<10	56	7	49	87,5%
10-14	60	13	47	78,3%
15-19	34	8	26	76,5%
20-24	17	5	12	70,6%
>=25	7	2	5	71,4%
Overall	174	35	139	79,9%

Yaşa göre sağkalım


- **<65 :** **n: 149**
- **1 y :** **89,0%**
- **3 y :** **84,9%**
- **5 y :** **79,6%**
- **≥65 :** **n: 25**
- **1 y :** **72,0%**
- **3 y :** **63,0%**
- **5 y :** **56,0%**



Mikrovasküler invazyon

Yok: **n=110**
1 y: **89,9%**
3 y: **85,4%**
5 y: **82,3%**

Var: **n=62**
1 y: **80,3%**
3 y: **74,7%**
5 y: **62,6%**



VASMIC	Total N	N of Events	Censored	
			N	Percent
YOK	110	17	93	84,5%
VAR	62	18	44	71,0%
Overall	172	35	137	79,7%

MİLAN

r-Milan içi: n=104

1 y: 87,2%

3 y: 84,6%

5 y: 78,4%

r-Milan dışı: n=42

1 y: 82,6%

3 y: 74,3%

5 y: 65,9%

p-Milan içi: n=108

1 y: 88,7%

3 y: 85,4%

5 y: 79,7%

p-Milan dışı: n=66

1 y: 82,9%

3 y: 75,5%

5 y: 70,1%

İnsidental: n=28

1 y: 89,3%

3 y: 81,8%

5 y: 81,8%

r-Milan

p-Milan


Case Processing Summary

radmilan	Total N	N of Events	Censored	
			N	Percent
beyond milan	42	12	30	71,4%
within milan	104	18	86	82,7%
incidental	28	5	23	82,1%


Case Processing Summary

patmilan	Total N	N of Events	Censored	
			N	Percent
beyond milan	66	17	49	74,2%
within milan	108	18	90	83,3%
Overall	174	35	139	79,9%

Survival Functions



Survival Functions



UCSF

- UCSF içi : n=124

1 y: 89,3%

3 y: 85,5%

5 y: 80,4%

- UCSF dışı : n=50

1 y: 79,6%


3 y: 72,4%

5 y: 65,9%

Case Processing Summary

UCSF	Total N	N of Events	Censored	
			N	Percent
beyond ucsf	50	15	35	70,0%
within ucsf	124	20	104	83,9%
Overall	174	35	139	79,9%

Survival Functions




Tümör diferansiyasyonu

Case Processing Summary

DIF	Total N	N of Events	Censored	
			N	Percent
WELL	42	6	36	85,7%
MOD	112	20	92	82,1%
POOR	18	9	9	50,0%
Overall	172	35	137	79,7%

Survival Functions

İyi	:	n=42
1 y:		88,1%
3 y:		84,9%
5 y:		84,9%
Orta	:	n=112
1 y:		90,9%
3 y:		85,7%
5 y:		77,3%
Kötü	:	n=18
1 y:		54,3%
3 y:		47,5%
5 y:		47,5%



Cox Regression Multivariate Analiz

	B	SE	Wald	df	Sig.	Exp(B)
radmilan	,312	,397	,618	1	,432	1,366
patmilan	,299	,771	,151	1	,698	1,349
UCSF	-,928	,797	1,355	1	,244	,395
AFP100	-,547	,804	,463	1	,496	,579
AFP200	-,242	,945	,065	1	,798	,785
AFP400	,073	,993	,005	1	,941	1,076
DIF	,842	,405	4,323	1	,038	2,320
TMNO	-,090	,247	,133	1	,715	,914
TMCAP	-,422	,528	,640	1	,424	,655
TOPTMCAP	-,185	,402	,212	1	,645	,831
VASMIC	,337	,431	,613	1	,433	1,401
VASMAC	,046	,689	,005	1	,947	1,047
Y65	,641	,478	1,796	1	,180	1,898
Y60	,213	,431	,244	1	,621	1,238

Kötü prognoz ne kadar kötü?

- Hasta >65 y (25) : 5-y sağkalım : %56
- Mikrovask. İnv.(62) : 5-y sağkalım : %62,6
- UCSF dışı (50) : 5-y sağkalım : %65,9
- Kötü dif. (18) : 5-y sağkalım : %47.5
- UCSF içi kötü dif. (10) : 5-y sağkalım : %60
- UCSF dışı kötü dif. (8) : 1-y sağkalım : %46
2-y sağkalım : %31,3

Sonuç

- **KC Tx en etkin HCC tedavi yöntemi**
- **HCC için KC Tx kriterleri genişletilmeli**
- **Tümör diferansiyasyonu en önemli faktör**
- **UCSF dışı grupta biyopsi yapılarak 5 yıllık sağkalımı %30 dan %67 ye çekilebilir**

Canlıdan KC naklinin tedaviye katkıları

- Yavaş biyoloji
- İyi/orta diferansiye
- Düzenli sınır
- Yaş <65
- İyi performans




Fig. 2. The BCLC staging system for HCC. M, metastasis classification; N, node classification; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.